Molecular Templates, Inc.

82 articles about Molecular Templates, Inc.

• Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169

  4/7/2023

  Molecular Templates, Inc., announced that the U.S. Food and Drug Administration informed MTEM that it has placed a partial clinical hold on the Phase 1 study of MT-0169 based on previously disclosed cardiac adverse events noted in two patients dosed at 50 mcg/kg that prompted the dose reduction to 5 mcg/kg last year.

• Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update

  3/30/2023

  Molecular Templates, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.

• Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4

  3/9/2023

  Molecular Templates, Inc. has received clearance by the United States Food and Drug Administration (“FDA”) following review of its Investigational New Drug Application (“IND”) to proceed for clinical testing of its novel MT-8421 ETB program targeting CTLA-4 in patients with relapsed/refractory solid tumors previously exposed to checkpoint inhibitors.

• Molecular Templates Announces Participation in Upcoming March 2023 Conferences

  3/1/2023

  Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies, to create novel therapies with potent differentiated mechanisms of action for cancer, announced participation in the following upcoming 2023 conferences.

• Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting

  12/2/2022

  Molecular Templates, Inc. announced that they will present a poster on interim clinical results for the MT-5111 program at the San Antonio Breast Cancer Symposium which will take place December 6 – December 10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, TX.

• Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper Sandler’s 34th Annual Healthcare Conference

  11/23/2022

  Molecular Templates, Inc. announced that CEO, Eric Poma, Ph.D., will present a virtual fireside chat at Evercore ISI’s 5th Annual HealthCONx conference which will take place November 29 – December 1, 2022, and an in-person fireside chat with an analyst Q&A portion at Piper Sandler’s 34th Annual Healthcare Conference in New York, NY which will take place November 29 – December 1, 2022.

• Molecular Templates, Inc. Reports Third Quarter 2022 Financial Results

  11/10/2022

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today reported financial results and business updates for the third quarter of 2022.

• Molecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

  11/4/2022

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today announced that it will present four abstracts and host an in-person Research & Development Day, Friday, November 11, 2022, at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting which will be held November 8 – 12, 2022 at the Boston Convention and Exhibition Center in Boston, MA.

• Molecular Templates Announces Participation in Four Upcoming Conferences

  8/31/2022

  Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular Templates” or “MTEM”) a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), will participate in the following September 2022 conferences.

• Molecular Templates, Inc. Reports Second Quarter 2022 Financial Results

  8/11/2022

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), today reported financial results and business updates for the second quarter of 2022.

• Molecular Templates’ Presentations at the 2022 ASCO Annual Meeting Demonstrate Advancement in PD-L1 and HER2 Programs

  6/6/2022

  Molecular Templates, Inc. announces highlights from the two poster presentations on its clinical programs that were presented on June 5th at the 2022 American Society of Clinical Oncology annual meeting, taking place June 3 through June 7, 2022 at the McCormick Place Convention Center in Chicago, IL.

• Molecular Templates to Present at Upcoming Investor Conferences - May 17, 2022

  5/17/2022

  Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies, will participate in the following upcoming investor conferences.

• Molecular Templates, Inc. Reports First Quarter 2022 Financial Results

  5/12/2022

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the first quarter of 2022.

• Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2022 Highlight Potential of ETB Approach

  4/12/2022

  Molecular Templates, Inc. reviews highlights from the six poster presentations on its pipeline programs that were presented at the American Association of Cancer Research (AACR) Annual Meeting 2022, taking place April 8 - April 13, 2022.

• Molecular Templates to Host Webinar on a Unique Approach to Immuno-Oncology for Solid Tumors

  4/8/2022

  Molecular Templates, Inc. announced that it will host a webinar on a unique approach to immuno-oncology for solid tumors on Wednesday, April 13, 2022 at 8:00 am Eastern Time.

• Molecular Templates, Inc. Reports Fourth Quarter 2021 Financial Results

  3/28/2022

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the fourth quarter of 2021.

• Molecular Templates Strengthens Board of Directors and Management Team

  3/2/2022

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced the appointment of Gabriela Gruia, M.D., to its Board of Directors and the promotion of Megan Filoon to General Counsel.

• Molecular Templates to Present at the Upcoming Investor Conferences - Mar 01, 2022

  3/1/2022

  Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies, which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, will participate in several upcoming investor conferences.

• Molecular Templates Provides Corporate Update and Outlines 2022 Milestones

  11/30/2021

  Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies, provided a corporate update and outlined expected 2022 milestones.

• Molecular Templates, Inc. Announces Fast Track Designation Granted by FDA for MT-6402

  11/18/2021

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for MT-6402 for the treatment of patients with advanced non-small cell lung cancer (NSCLC) expressing PD-L1.